Maternal Cell Contamination (MCC): The Hidden Risk in Prenatal Genetic Testing
When you have an amniocentesis or CVS, you expect the lab to test your baby’s DNA — not yours. But sometimes maternal cells sneak into the sample. That’s maternal cell contamination (MCC), and it’s one of the leading causes of misdiagnosis in prenatal testing.
What is maternal cell contamination?
Maternal cell contamination occurs when a fetal specimen comes into contact with maternal blood or tissue. The risk of MCC is associated with procedures such as chorionic villus sampling, amniocentesis, or extraction of fetal blood from the umbilical cord.
If MCC is present, the maternal DNA may mask the results of any genetic testing performed on the fetal DNA. Therefore, the results of prenatal testing may be compromised.
Prenatal samples obtained by amniocentesis or chorionic villus sampling (CVS) are at risk of contamination by maternal cells. The most common cause of MCC is the presence of maternal blood in amniotic fluid and maternal decidua in CVS.
How common is MCC?
The numbers are higher than most patients expect:
- Risk is calculated as approximately 0.5% in AF and 1–2% in CVS
- Contaminating maternal blood can be visualized in 1% to 2% of amniotic fluid samples and in up to 38% of pelleted amniocytes following centrifugation
- Highly sensitive molecular testing has identified MCC in 9.1% of direct or cultured fetal cell preparations, 17.8% of which had no visible evidence of maternal blood
- In CVS for peroxisomal disorders, studies show a 2.5% risk of maternal cell contamination
CVS carries higher risk than amnio because it’s difficult to accurately remove the maternal decidua from the fetal cells.
Why MCC matters: the clinical impact
Even low levels of contamination that are below visual detection may negatively impact molecular, biochemical, or cytogenetic results.
Contamination of a CVS sample with cells of maternal origin may result in analysis of the maternal rather than the fetal karyotype or genotype, especially when the sample size is small.
Real-world consequences:
- False-negative for a recessive disorder (maternal normal DNA masks fetal mutation)
- False-positive carrier result
- Incorrect sex determination
- Misdiagnosis leading to termination or continuation decisions
That’s why professional guidelines recommend MCC testing in prenatal diagnosis.
How labs detect MCC
Modern MCC testing doesn’t rely on looking at the sample — it uses DNA fingerprinting.
The standard method: STR analysis
Labs compare highly polymorphic short tandem repeat/microsatellite loci between maternal and fetal DNA samples following PCR. Tetranucleotide/pentanucleotide markers are preferable due to superior fidelity and robustness.
Current practice:
- Most labs use commercial assays with 4–16 markers
- Mayo Clinic’s MATCC test evaluates over 80 polymorphic variants at 10 loci
- UW Medicine uses next-generation sequencing to analyze 80 polymorphic variants at 10 loci, with contamination flagged when maternal cells exceed 5–20%
A simple approach using polymorphic loci like D1S80 and THO1 identified 90% of cases via one polymorphic locus in a study of 135 cases.
Sensitivity
Molecular sensitivity is typically ≥10% for detecting MCC, though low-level DNA contamination (1–5%) may be detectable via genotyping but requires ∼10% for definitive results.
Laboratory guidelines: what should happen
The Association for Molecular Pathology recommends:
- To determine the pure fetal origin of all prenatal specimens, MCC analysis should be performed in parallel with diagnostic testing, regardless of disorder
- Maternal specimen (blood or buccal) should be collected at same time as fetal sample
- MCC testing should be performed on DNA extracted from the same sample used for diagnostic testing
Only a maternal peripheral blood or buccal sample is strictly required for MCC testing. Paternal samples are not helpful.
How labs prevent MCC
Prevention starts at collection:
- For amnio: discard first 1–2 ml (may contain maternal skin cells), use Doppler ultrasound to avoid placenta, use 22G needle (21G increases contamination risk)
- For CVS: thoroughly examine under dissecting microscope to remove maternal decidua before culture
- Culture helps: MCC occurs at significantly lower rate among AF cultures than direct AF samples, because culture conditions favor amniocytes and reduce maternal blood cells
When is MCC testing mandatory?
Guidelines say: always. But in practice, 60% of US labs perform MCC testing, and practices vary.
You should insist on MCC testing if:
- Direct (uncultured) amniotic fluid or CVS
- Small sample volume
- Testing for recessive disorders
- Mosaic results
- Discordant ultrasound and genetic results
- Multiple gestation (to rule out co-twin contamination)
Interpreting MCC results
Labs report:
- No MCC detected: <5% maternal DNA
- Low-level MCC: 5–10% — may proceed with caution, often culture
- Significant MCC: >10–20% — requires new sample or cultured cells
Two to three informative microsatellite markers reflecting clearly definable, separate maternal and fetal genotypes from among a panel of 7–10 markers should be used to assess MCC.
New technologies improving detection
Three methods using Bayesian models and machine learning improve fetal variant calling accuracy when MCC is present, outperforming traditional methods.
Chip-based digital PCR achieved 90% accuracy for trisomy 21, 85% for trisomy 18, and 92% for X monosomy even with contamination.
What patients should ask
Before your amnio or CVS, ask:
- “Do you perform maternal cell contamination testing on every sample?”
- “Will you collect my blood/buccal sample at the same time?”
- “What is your lab’s MCC detection threshold?”
- “If MCC is found, what’s the backup plan?”
If the answer is “we don’t routinely test,” consider another lab. MCC analysis may also be used as internal quality assurance to ensure the biological mother is matched with her fetus, minimizing sample mix-up.
Bottom line
Maternal cell contamination is not rare — it’s found in up to 9% of prenatal samples with sensitive testing, and visual inspection misses most cases. The risk is higher with CVS (1–2%) than amniocentesis (0.5%).
The good news: MCC is preventable and detectable. With proper sample handling, maternal comparison, and STR-based testing, labs can ensure your results reflect your baby, not you.
Always ensure your prenatal genetic test includes MCC analysis. It’s a small step that prevents the biggest error in prenatal diagnosis.
